BSLN — Basilea Pharmaceutica AG Allschwil Balance Sheet
0.000.00%
- CH₣600.87m
- CH₣554.48m
- CH₣208.54m
- 69
- 64
- 80
- 87
Annual balance sheet for Basilea Pharmaceutica AG Allschwil, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
| 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | ARS | ARS | ARS | ARS | ARS | 
| Standards: | USG | USG | USG | USG | USG | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 162 | 149 | 84.7 | 59.9 | 121 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 32.4 | 64.4 | 61.7 | 58.1 | 58.2 | 
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 224 | 241 | 175 | 152 | 221 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.28 | 2.92 | 21.6 | 20.6 | 19 | 
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 230 | 247 | 221 | 173 | 258 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 50.2 | 174 | 74.8 | 47.6 | 45.6 | 
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 332 | 306 | 242 | 183 | 177 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | -102 | -58.6 | -20.7 | -10 | 81 | 
| Total Liabilities & Shareholders' Equity | 230 | 247 | 221 | 173 | 258 | 
| Total Common Shares Outstanding |